A mounting artificial intelligence (AI) bubble, overvalued markets and resource nationalism are among the issues experts at the 51st New Orleans Investment Conference flagged for investors heading into 2026. With…
-
-
Investor Insight InMed is a pharmaceutical drug development company advancing proprietary small-molecule drugs in Alzheimer’s and ophthalmology, backed by a revenue-generating manufacturing subsidiary. The company is an undervalued opportunity with…
-
-
-
Graphite One (TSXV:GPH,OTCQX:GPHOF) announced on November 13 that it has identified rare earth elements (REEs) at its Graphite Creek deposit, located north of Nome, Alaska. “The presence of two Defense…
-
Researchers have documented the first known recovery of naturally formed nanoscale monazite from a living plant, potentially opening up new paths to recover in-demand rare earth materials. The study, published…
-
East Star Resources (LSE:EST) and Endeavour Exploration announced they have entered into a binding earn-in and joint venture (JV) agreement to advance gold exploration in Kazakhstan. Endeavour Exploration, a subsidiary…
-
Rio Tinto (ASX:RIO,NYSE:RIO,LSE:RIO) said on Monday (November 17) that it has signed a joint development agreement with environmental technology company Calix (NYSE:CALX,ASX:CXL) to develop Calix’s Zero Emissions Steel Technology (Zesty)…
-
Investing
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer’s Disease Candidate INM-901
Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) (‘InMed’ or the ‘Company’), a pharmaceutical…
-